Trade CGEM stock anytime, 24x5 in Singapore
Regulated by
Monetary Authority of Singapore (MAS)
Trusted by
400,000+ users
Cullinan Therapeutics, Inc. (CGEM) is trading at US$11.31, up 4.72% today as of Nov 6, 16:00 EST. The company has a market capitalisation of US$1.4B. Over the past 52 weeks, CGEM has traded between US$6.73 and US$23.19. On Syfe you can trade CGEM with $0 commission and add it to your watchlist.
| Previous close | US$10.80 |
|---|---|
| Market cap | US$1.4B |
| 52-week range | US$6.73 – US$23.19 |
| Volume | 1.78M |
| Exchange | US |
Cullinan Therapeutics, Inc.
Cullinan Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the developing of oncology and immuno-oncology therapies. Its pipeline includes CLN-978, CLN-619, Zipalertinib CLN-081/TAS6417, CLN-049, and CLN-617. The company was founded by Patrick A. Baeuerle on September 15, 2016 and is headquartered in Cambridge, MA.
Year: 2021
Sector Update: Healthcare Stocks Edge Higher Pre-Bell Friday
Oct 2, 1:19 PM · MT Newswires
Cullinan Starts FDA Submission for Zipalertinib-Chemotherapy Combo in Non-Small Cell Lung Cancer
Oct 2, 8:10 AM · MT Newswires
UBS Adjusts Cullinan Therapeutics Price Target to $27 From $24, Maintains Buy Rating
Aug 17, 2:05 PM · MT Newswires
Cullinan Therapeutics, Inc. (CGEM) stock is trading at US$11.31, +4.72% from the previous close of US$10.80.
The market cap for Cullinan Therapeutics, Inc. (CGEM) stock is approximately US$1.4B.
The 52-week high for Cullinan Therapeutics, Inc. (CGEM) stock is US$23.19.
The 52-week low for Cullinan Therapeutics, Inc. (CGEM) stock is US$6.73.
Cullinan Therapeutics, Inc. (CGEM) does not currently pay a dividend.
Stay on top of CGEM
Price moves, news and earnings — straight to your inbox.
Snapshot
Popular Stocks in Singapore
